Stock Events

Stock Events

Structure Therapeutics 

$53.48
30
+$3.31+6.6% Thursday 20:00

Statistics

Day High
55.75
Day Low
48
52W High
94.9
52W Low
13.22
Volume
1,707,512
Avg. Volume
1,060,660
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

9MayExpected
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q1 2024
-1.14
-0.76
-0.38
0
Expected EPS
-0.22
Actual EPS
0

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-282.4MNet Income

Analyst Ratings

$110.78Average Price Target
The highest estimate is 140.00.
From 9 ratings within the last 6 months. This is not an investment recommendation.
Buy
89%
Hold
11%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GPCR. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals is a leader in treating cystic fibrosis, a focus area that overlaps with Structure Therapeutics' GPCR-targeted therapies, making them direct competitors in drug development for similar diseases.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences focuses on antiviral drugs for infections like HIV, hepatitis B, hepatitis C, and influenza, areas where Structure Therapeutics could potentially compete through its GPCR-focused therapies.
AMGEN
AMGN
Mkt Cap160.66B
Amgen operates in various therapeutic areas, including cardiovascular disease, oncology, and inflammation, competing with Structure Therapeutics in the broad scope of drug development and innovation.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals is known for its innovation in biopharmaceuticals, directly competing with Structure Therapeutics in the development of novel therapies targeting GPCRs.
Biogen
BIIB
Mkt Cap22.63B
Biogen focuses on neurological diseases, an area where Structure Therapeutics' GPCR-targeted approach could offer competitive therapeutic options.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie operates in areas including immunology and oncology, where Structure Therapeutics' GPCR-focused drug development could present direct competition.
Merck
MRK
Mkt Cap214.76B
Merck & Co. is a global healthcare company that could compete with Structure Therapeutics in various therapeutic areas through its extensive drug development pipeline.
Pfizer
PFE
Mkt Cap140.15B
Pfizer's broad range of therapeutic areas and significant R&D investment make it a competitor to Structure Therapeutics, especially in GPCR-targeted drug development.
Novartis
NVS
Mkt Cap237.61B
Novartis focuses on a wide range of healthcare areas, including the rapidly evolving field of targeted therapies where Structure Therapeutics operates.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca has a diverse portfolio in respiratory, cardiovascular, renal, metabolism, and oncology, competing with Structure Therapeutics in the development of novel therapeutics.

About

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.
Show more...
CEO
Dr. Raymond C. Stevens Ph.D.
Employees
163
Country
KY
ISIN
US86366E1064

Listings

XNAS
US
GPCR
BOATS
BOATS
GPCR.BOATS

0 Comments

Share your thoughts

FAQ

What is Structure Therapeutics stock price today?▼
The current price of GPCR is $53.48 USD — it has increased by +6.6% in the past 24 hours. Watch Structure Therapeutics stock price performance more closely on the chart.
What is Structure Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Structure Therapeutics stocks are traded under the ticker GPCR.
Is Structure Therapeutics stock price growing?▼
GPCR stock has risen by +16.46% compared to the previous week, the month change is a -15.29% fall, over the last year Structure Therapeutics has showed a +253.7% increase.
What were Structure Therapeutics earnings last quarter?▼
GPCR earnings for the last quarter are 0 USD per share, whereas the estimation was -0.22 USD resulting in a +100% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Structure Therapeutics revenue for the last year?▼
Structure Therapeutics revenue for the last year amounts to 0 USD.
What is Structure Therapeutics net income for the last year?▼
GPCR net income for the last year is -282.4M USD.
How many employees does Structure Therapeutics have?▼
As of April 04, 2026, the company has 163 employees.
In which sector is Structure Therapeutics located?▼
Structure Therapeutics operates in the Health Care sector.
When did Structure Therapeutics complete a stock split?▼
Structure Therapeutics has not had any recent stock splits.
Where is Structure Therapeutics headquartered?▼
Structure Therapeutics is headquartered in South San Francisco, KY.